A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer
Latest Information Update: 19 Aug 2022
At a glance
- Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors PharmAbcine
- 15 Aug 2022 Planned End Date changed from 26 Feb 2022 to 26 Oct 2022.
- 25 Feb 2022 According to a PharmAbcine media release, last patient last visit has been completed in the trial. The last patient, who just completed 35 cycles of olinvacimab and pembrolizumab combo treatment, will receive olinvacimab in monotherapy as compassionate use starting from early March 2022. In addition, another patient, who showed CR in the target lesion, has already been receiving olinvacimab as compassionate use since August 2021 and is in stable condition.
- 09 Sep 2021 According to PharmAbcine media release, a Patent Cooperation Treaty (PCT) application was submitted jointly with Merck Sharp & Dohme for the combination therapy of olinvacimab, the Company anti-VEGFR2 antibody, and KEYTRUDA (pembrolizumab), MSDs anti-PD-1 antibody, for the treatment of cancer based on this trial